# US 2013/0156808 A1 · Vaccine comprising beta-herpesvirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156808 A1
- Document ID: US20130156808A1
- Status: Published application
- Kind: A1
- Application number: 13/684,241
- Filed: 2012-11-22
- Published: 2013-06-20
- Earliest claimed: 2011-11-22
- Inventors: Stipan Jonjic
- Web page: https://patentgrep.com/patent/US20130156808A1

## CPC

- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0208: {Specific bacteria not otherwise provided for}
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 39/12: Viral antigens
- A61K 40/00: Cellular immunotherapy (medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/46: Viral antigens
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 7/045: {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2710/16121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16143: viral genome or elements thereof as genetic vector
- C12N 2710/16162: by genetic engineering
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a beta-herpesvirus, preferably a recombinant beta-herpesvirus, wherein the beta-herpesvirus comprises at least one heterologous nucleic acid, wherein the at least one heterologous nucleic acid comprises a gene encoding a cellular ligand.

## Claims

### Claim 1

A beta-herpesvirus, preferably a recombinant beta-herpesvirus, wherein the beta-herpesvirus comprises at least one heterologous nucleic acid, wherein the at least one heterologous nucleic acid comprises a gene encoding a cellular ligand.

### Claim 2 (depends on 1)

The beta-herpesvirus according to claim 1, wherein the cellular ligand is capable of binding a receptor for the cellular ligand wherein the receptor for the cellular ligand is present on the surface of at least one immune cell, and wherein the at least one immune cell is selected from the group consisting of NK cells, γδ T cells and activated CD8+ T cells.

### Claim 3 (depends on 1)

The beta-herpesvirus according to claim 1, wherein the cellular ligand is an NKG2D ligand.

### Claim 4 (depends on 3)

The beta-herpesvirus according to claim 3, wherein the NKG2D ligand is a human NKG2D ligand is selected from the group consisting of UL16 binding proteins and MHC class-1-related protein.

### Claim 5 (depends on 4)

The beta-herpesvirus according to claim 4, wherein the UL16 binding protein is selected from the group consisting of ULBP2, ULPB1, ULBP3, ULBP4, ULBP5 and ULBP6.

### Claim 6 (depends on 4)

The beta-herpesvirus according to claim 4, wherein the MHC class-1-related protein is selected from the group consisting of MICA and MICB.

### Claim 7 (depends on 1)

The beta-herpesvirus according to claim 1, wherein the beta-herpesvirus is suitable for inducing an immune response against a beta-herpesvirus, wherein the immune response comprises neutralizing antibodies against beta-herpesvirus and/or CD4+ T-cells directed against epitopes of beta-herpesvirus and/or CD8+ T-cells directed against epitopes of beta-herpesvirus.

### Claim 8 (depends on 1)

The beta-herpesvirus according to claim 1, wherein the beta-herpesvirus is human cytomegalovirus.

### Claim 9 (depends on 1)

The beta-herpesvirus of claim 1, wherein the beta-herpesvirus is deficient in at least one gene product encoded by an immune modulatory gene.

### Claim 10 (depends on 9)

The beta-herpesvirus according to claim 9, wherein the at least one immune modulatory gene is selected from the group consisting of UL16 and UL142.

### Claim 11 (depends on 9)

The beta-herpesvirus according to claim 9, wherein the beta-herpesvirus is deficient in one or more additional gene product(s) each encoded by an additional immune modulatory gene.

### Claim 12 (depends on 11)

The beta-herpesvirus according to claim 11, wherein the at least one additional gene product encoded by the additional immune modulatory gene is a gene product regulating NK cell response encoded by an immune modulatory gene selected from the group consisting of UL16, UL18, UL40, UL142, m152, m155, m145 and m138.

### Claim 13 (depends on 11)

The beta-herpesvirus of claim 11, wherein the at least one additional gene product encoded by the additional immune modulatory gene is a gene product regulating MHC class I presentation, wherein the gene product regulating MHC class I presentation is a gene product encoded by an immune modulatory gene selected from the group consisting of US6, US3, US2 and US11.

### Claim 14 (depends on 1)

The beta-herpesvirus according to claim 1, wherein the beta-herpesvirus comprises the deletion of at least one miRNA.

### Claim 15 (depends on 1)

The beta-herpesvirus according to claim 1, wherein the beta-herpesvirus is deficient in at least one gene product encoded by a gene regulating viral replication, wherein the gene regulating viral replication is selected from the group consisting of IE1, pp 71 and pp65.

### Claim 16 (depends on 1)

The beta-herpesvirus according to claim 1, wherein the beta-herpesvirus is deficient in at least one gene product encoded by an essential gene, wherein the essential gene is selected from the group consisting of UL32, UL34, UL37.1, UL44, UL46, UL48, UL48, UL49, UL50, UL51, UL52, UL53, UL54, UL55, UL56, UL57, UL60, UL70, UL71, UL73, UL75, UL76, UL77, UL79, UL80, UL84, UL85, UL86, UL87, UL89.1, UL90, UL91, UL92, UL93, UL94, UL95, UL96, UL98, UL99, UL100, UL102, UL104, UL105, UL115 and UL122.

### Claim 17 (depends on 1)

The beta-herpesvirus according to claim 1, wherein the beta-herpesvirus is deficient in at least one glycoprotein.

### Claim 18 (depends on 1)

The beta-herpesvirus according to claim 1, wherein the beta-herpesvirus encodes at least one additional heterologous nucleic acid.

### Claim 19 (depends on 18)

The beta-herpesvirus according to claim 18, wherein the at least one additional heterologous nucleic acid is a functional nucleic acid selected from the group consisting of antisense molecules, ribozymes and RNA interference mediating nucleic acids or wherein the at least one additional heterologous nucleic acid is a heterologous nucleic acid coding for a peptide, oligopeptide, polypeptide or protein.

### Claim 20 (depends on 19)

The beta-herpesvirus according to claim 19, wherein the peptide, oligopeptide, polypeptide or protein constitutes or comprises at least one antigen, wherein the antigen is an antigen selected from the group consisting of tumor antigens, tumor associated antigens, viral antigens, bacterial antigens and parasite antigens.

### Claim 21 (depends on 20)

The beta-herpesvirus according to claim 20, wherein the viral antigen is an antigen derived from a virus, wherein the virus is selected from the group consisting of HIV, Influenza, HPV and RSV.

### Claim 22 (depends on 20)

The beta-herpesvirus according to claim 20, wherein the bacterial antigen is an antigen derived from a bacterium, wherein the bacterium is selected from the group consisting of mycobacterium, Helicobacter pylori and Listeria.

### Claim 23 (depends on 20)

The beta-herpesvirus according to claim 20, wherein the parasite antigen is an antigen derived from a parasite, wherein the parasite is selected from the group consisting of Plasmodium.

### Claim 24 (depends on 1)

A method for the treatment or prevention of a disease comprising administering to a subject the beta-herpesvirus according to claim 1.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the disease is a disease or condition which is associated with beta-herpesvirus infection.

### Claim 26 (depends on 24)

The method according to claim 24, wherein the disease is a disease selected from the group consisting of bacterial disease, viral disease, parasite disease and tumors, wherein the beta-herpesvirus is expressing a bacterial antigen, a viral antigen, a parasite antigen or a tumor antigen.

### Claim 27 (depends on 1)

A method for the vaccination of a subject against a diseases, comprising the administration to the subject of the beta-herpesvirus according to claim 1.

### Claim 28 (depends on 1)

A nucleic acid coding for a beta-herpesvirus as defined in claim 1.

### Claim 29 (depends on 28)

An expression vector, comprising the nucleic acid according to claim 28.

### Claim 30 (depends on 1, 28)

A pharmaceutical composition comprising a beta-herpesvirus according to claim 1 and/or a nucleic acid according to claim 28, and a pharmaceutically acceptable carrier.